Thus, using a non-alloreactive cell therapy approach and a physiologically relevant mouse tumor model of triple-negative breast cancer, we demonstrate the pre-clinical efficacy of FAP CAR T-cell pre-treatment to reprogram the ‘cold’ TME and make the tumor susceptible to subsequent Mesothelin CAR T-cell cytotoxicity. This evidence concerns the gene FAP and neoplasm.